Oral contraceptives use reduces ovarian and endometrial cancer risk
| Autor: | Anca Marina Ciobanu, Pharmacy, Bucharest, Romania, Radu Botezatu, Gheorghe Peltecu, Anca Maria Panaitescu, Brînduşa Ana Cimpoca-Raptis, Nicolae Gică, Corina Gică, Teodora Cioroba |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Romanian Journal of Medical Practice. 16:45-49 |
| ISSN: | 2069-6108 1842-8258 |
| DOI: | 10.37897/rjmp.2021.s3.10 |
| Popis: | One of the greatest problems that patients and medical system confront worldwide nowadays is cancer. Even if there is a great focus on treatment improvement, it is equally or even more important to find cancer prevention pathways. If we concentrate on gynecological malignancies, we have as example cervical cancer which can now be prevented through vaccination, but less is known about prevention methods for endometrial and ovarian cancer. In 1992, Alice S. Whittemore first described the protective role of combined oral contraceptives (COC) use against ovarian cancer. After that, many other studies tried to find out how combined oral contraceptive use influence the risk of gynecological cancers. According to all researches, it is now known that COC are associated with risk reduction in ovarian and endometrial cancers. It was observed that their risk reduction depends on different factors such as length of use, the period of life when they were used, or some other associated risk factors. Moreover, it seems that they offer protection only against some histological types of endometrial and ovarian cancer. This review relates the most important findings regarding COC use and their risk reduction effect on ovarian and endometrial cancer in the recent studies. Even if some certain conclusions were made, such as time-dependent effect, more studies need to be conducted in order to have certain future recommendations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|